介入术后冠脉无复流的危险因素识别与药物治疗

冠脉无复流现象（NRP）作为经皮冠状动脉介入治疗（PCI）过程中的常见并发症，尤其高发于急诊PCI术中。无复流区范围随血运重建时间延长而扩大，是一种影响预后的独立危险因素，可导致梗塞面积扩大，左心室重塑，心律失常或复发胸痛等主要不良心脏事件（MACE）发生率显著增加。目前已有多种药用方案来预防无复流，主要包括硝普钠、维拉帕米、替罗非班、腺苷、尼可地尔、山莨菪碱等，其疗效各有优劣，现就无复流的判断及治疗做一综述。

Identification of Risk Factors and Drug Therapy for Postoperative Coronary Artery No-reflow

Coronary no-reflow (NRP) is a common complication in percutaneous coronary intervention (PCI), especially in emergency PCI. The extent of no-reflow area expands with prolonged revascularization time and is an independent risk factor for prognosis, which can lead to an enlarged infarct size, left ventricular remodeling, arrhythmia or recurrent chest pain and other major adverse cardiac events (MACE). A significant increase. At present, there are a variety of medicinal programs to prevent no-reflow, mainly including sodium nitroprusside, verapamil, tirofiban, adenosine, nicorandil, and anisodamine. Now I will review the judgment and treatment of no reflow.